Tryptamine Therapeutics Limited (ASX:TYP)
Australia
· Delayed Price · Currency is AUD
0.0300
+0.0010 (3.45%)
Last updated: Jun 26, 2025
Tryptamine Therapeutics Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Jun '24 Jun 30, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | Aug '21 Aug 31, 2021 | Aug '20 Aug 31, 2020 |
| Revenue | 1.33 | - | - | - | - |
| Cost of Revenue | 2.35 | 2.62 | - | - | - |
| Gross Profit | -1.02 | -2.62 | - | - | - |
| Selling, General & Admin | 1.82 | 2.45 | 4.59 | 3.84 | 0.47 |
| Research & Development | - | - | 3.3 | 1.39 | 0.01 |
| Operating Expenses | 3.61 | 2.45 | 8.2 | 7.89 | 0.48 |
| Operating Income | -4.63 | -5.07 | -8.2 | -7.89 | -0.48 |
| Interest Expense | -0.65 | -0.79 | - | - | - |
| Interest & Investment Income | 0.02 | 0 | 0 | 0.01 | - |
| Currency Exchange Gain (Loss) | -0 | - | -0.15 | -0.02 | - |
| EBT Excluding Unusual Items | -5.27 | -5.85 | -8.35 | -7.9 | -0.48 |
| Asset Writedown | - | - | - | -1.04 | - |
| Other Unusual Items | -2.1 | - | - | - | - |
| Pretax Income | -7.37 | -5.85 | -8.35 | -8.94 | -0.48 |
| Net Income | -7.37 | -5.85 | -8.35 | -8.94 | -0.48 |
| Net Income to Common | -7.37 | -5.85 | -8.35 | -8.94 | -0.48 |
| Shares Outstanding (Basic) | 507 | 349 | 78 | 51 | - |
| Shares Outstanding (Diluted) | 507 | 349 | 78 | 51 | - |
| Shares Change (YoY) | 45.33% | 346.62% | 51.73% | - | - |
| EPS (Basic) | -0.01 | -0.02 | -0.11 | -0.17 | - |
| EPS (Diluted) | -0.01 | -0.02 | -0.11 | -0.17 | - |
| Gross Margin | -76.85% | - | - | - | - |
| Operating Margin | -349.01% | - | - | - | - |
| Profit Margin | -555.37% | - | - | - | - |
| EBITDA | -4.62 | - | - | - | - |
| D&A For EBITDA | 0.01 | - | - | - | - |
| EBIT | -4.63 | -5.07 | -8.2 | -7.89 | -0.48 |
| Revenue as Reported | 1.34 | 0 | - | - | - |
Source: S&P Global Market Intelligence. Standard template.
Financial Sources.